Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, mult...

por Markóczy, Zsolt, Sárosi, Veronika, Kudaba, Iveta, Gálffy, Gabriella, Turay, Ülkü Yilmaz, Demirkazik, Ahmet, Purkalne, Gunta, Somfay, Attila, Pápai-Székely, Zsolt, Rásó, Erzsébet, Ostoros, Gyula
Publicado 2018

Significant changes in advanced lung cancer survival during the past decade in Hungary: impact of modern immunotherapy and the COVID-19 pandemic

por Kiss, Zoltán, Gálffy, Gabriella, Müller, Veronika, Moldvay, Judit, Sárosi, Veronika, Pápai-Székely, Zsolt, Csada, Edit, Kerpel-Fronius, Anna, Király, Zsolt, Szász, Zoltán, Hódi, Gábor, Polányi, Zoltán, Kovács, Krisztina, Karamousouli, Eugenia, Knollmajer, Kata, Szabó, Tamás G., Berta, Andrea, Vokó, Zoltán, Rokszin, György, Abonyi-Tóth, Zsolt, Barcza, Zsófia, Tamási, Lilla, Bogos, Krisztina
Publicado 2023